Who are verapamil plus lithium's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/verapamil-plus-lithium.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

verapamil plus lithium — Competitive Intelligence Brief

verapamil plus lithium (verapamil plus lithium) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination therapy (calcium channel blocker + mood stabilizer). Area: Psychiatry / Cardiology (indication-dependent).

phase 3 Combination therapy (calcium channel blocker + mood stabilizer) L-type calcium channels (verapamil); inositol monophosphatase and GSK-3 (lithium) Psychiatry / Cardiology (indication-dependent) Small molecule Live · refreshed every 30 min

Target snapshot

verapamil plus lithium (verapamil plus lithium) — University of Pittsburgh. Verapamil (a calcium channel blocker) combined with lithium (a mood stabilizer) works synergistically to modulate cardiac conduction and neuronal signaling pathways.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
verapamil plus lithium TARGET	verapamil plus lithium	University of Pittsburgh	phase 3	Combination therapy (calcium channel blocker + mood stabilizer)	L-type calcium channels (verapamil); inositol monophosphatase and GSK-3 (lithium)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination therapy (calcium channel blocker + mood stabilizer) class)

University of Pittsburgh · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). verapamil plus lithium — Competitive Intelligence Brief. https://druglandscape.com/ci/verapamil-plus-lithium. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab